Emmaus Life Sciences, Inc. cotiza a 0.04 USD y tiene una capitalización bursátil de $3M. En los últimos 12 meses ha facturado $16M con un margen de flujo de caja libre del -0.1%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications…
| Periodo | 2023-05 | 2023-03 | 2022-11 | 2022-08 |
|---|---|---|---|---|
| Real | $-0.07 | $0.01 | $-0.01 | $-0.18 |
| Estimado | $-0.03 | $0.16 | $0.01 | $0.01 |
| Sorpresa | -133.3% | -93.8% | -200.0% | -1900.0% |
| Métrica | EMMA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 93.1% | 57.0% | +36.1% |
| Operating Margin | 1.9% | -38.6% | +40.5% |
| Net Margin | -60.2% | -33.6% | -26.6% |
| FCF Margin | -0.1% | -13.9% | +13.8% |
| ROE | — | -40.4% | — |
| ROA | -35.0% | -32.0% | -2.9% |
| Current Ratio | 0.11 | 2.84 | -2.73 |
| Debt / Equity | -0.43 | 0.28 | -0.71 |